scholarly journals Management Approach to Acute Myeloid Leukemia Leveraging the Available Resources in View of the Latest Evidence: Consensus of the Saudi Society of Blood and Marrow Transplantation

2021 ◽  
pp. 1220-1232
Author(s):  
Bader Alahmari ◽  
Mohsen Alzahrani ◽  
Nawal Al Shehry ◽  
Osamah Tawfiq ◽  
Turki Alwasaidi ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Saudi Arabia ◽  
Myeloid Leukemia ◽  
Treatment Algorithm ◽  
Review Literature ◽  
Management Approach ◽  
Blood And Marrow Transplantation ◽  
Epidemiologic Data ◽  
Recent Developments ◽  
Acute Myeloid

PURPOSE Acute myeloid leukemia (AML) is the most prevalent acute leukemia in adults and is responsible for the majority of cancer-related mortality. In Saudi Arabia, leukemia is ranked the fifth most prevalent type of malignancy in adults. Our aim is to review existing epidemiologic data in Saudi Arabia and develop consensus guidelines for management of AML. METHODS We review literature related to AML epidemiology, treatment patterns, and outcomes in Saudi Arabia, as well as literature related to the current advances in AML treatment. A panel of 10 experts from eight institutions in Saudi Arabia reviewed the literature and developed a consensus statement. RESULT We provide an update of the available AML epidemiologic data in Saudi Arabia and describe recent developments in the diagnostic workup, risk stratification, and treatment algorithm. The consensus recommendations for the management of AML in Saudi Arabia were developed. CONCLUSION The recommendations are in parallel with the recent international guidelines for the diagnosis and management of AML.

scholarly journals FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm

2021 ◽  
Vol 11 (5) ◽  
Author(s):  
Naval Daver ◽  
Sangeetha Venugopal ◽  
Farhad Ravandi
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Single Agent ◽  
Prognostic Significance ◽  
Treatment Algorithm ◽  
Molecular Testing ◽  
Prognostic Impact ◽  
Cell Transplant ◽  
Newly Diagnosed ◽  
Acute Myeloid

AbstractApproximately 30% of patients with newly diagnosed acute myeloid leukemia (AML) harbor mutations in the fms-like tyrosine kinase 3 (FLT3) gene. While the adverse prognostic impact of FLT3-ITDmut in AML has been clearly proven, the prognostic significance of FLT3-TKDmut remains speculative. Current guidelines recommend rapid molecular testing for FLT3mut at diagnosis and earlier incorporation of targeted agents to achieve deeper remissions and early consideration for allogeneic stem cell transplant (ASCT). Mounting evidence suggests that FLT3mut can emerge at any timepoint in the disease spectrum emphasizing the need for repetitive mutational testing not only at diagnosis but also at each relapse. The approval of multi-kinase FLT3 inhibitor (FLT3i) midostaurin with induction therapy for newly diagnosed FLT3mut AML, and a more specific, potent FLT3i, gilteritinib as monotherapy for relapsed/refractory (R/R) FLT3mut AML have improved outcomes in patients with FLT3mut AML. Nevertheless, the short duration of remission with single-agent FLT3i’s in R/R FLT3mut AML in the absence of ASCT, limited options in patients refractory to gilteritinib therapy, and diverse primary and secondary mechanisms of resistance to different FLT3i’s remain ongoing challenges that compel the development and rapid implementation of multi-agent combinatorial or sequential therapies for FLT3mut AML.

scholarly journals Circular RNAs in Hematopoiesis with a Focus on Acute Myeloid Leukemia and Myelodysplastic Syndrome

2020 ◽  
Vol 21 (17) ◽  
pp. 5972
Author(s):  
Michaela Dostalova Merkerova ◽  
Zdenek Krejcik ◽  
Katarina Szikszai ◽  
David Kundrat
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myelodysplastic Syndrome ◽  
Myeloid Leukemia ◽  
Experimental Methods ◽  
Circular Rnas ◽  
Specific Expression ◽  
Hematopoietic Stem ◽  
Recent Developments ◽  
Disease Specific ◽  
Acute Myeloid

Circular RNAs (circRNAs) constitute a recently recognized group of noncoding transcripts that function as posttranscriptional regulators of gene expression at a new level. Recent developments in experimental methods together with rapidly evolving bioinformatics approaches have accelerated the exploration of circRNAs. The differentiation of hematopoietic stem cells into a broad spectrum of specialized blood lineages is a tightly regulated process that depends on a multitude of factors, including circRNAs. However, despite the growing number of circRNAs described to date, the roles of the majority of them in hematopoiesis remain unknown. Given their stability and disease-specific expression, circRNAs have been acknowledged as novel promising biomarkers and therapeutic targets. In this paper, the biogenesis, characteristics, and roles of circRNAs are reviewed with an emphasis on their currently recognized or presumed involvement in hematopoiesis, especially in acute myeloid leukemia and myelodysplastic syndrome.

Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT)

Blood ◽  
2006 ◽  
Vol 109 (7) ◽  
pp. 2794-2796 ◽  
Author(s):  
Gerard Socie ◽  
Jean-Yves Mary ◽  
Hubert Schrezenmeier ◽  
Judith Marsh ◽  
Andrea Bacigalupo ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Aplastic Anemia ◽  
Myeloid Leukemia ◽  
Standard Treatment ◽  
Severe Aplastic Anemia ◽  
First Line ◽  
Blood And Marrow Transplantation ◽  
Stimulating Factor ◽  
European Group ◽  
Acute Myeloid

Abstract Previous studies suggested a link between the use of G-CSF and increased incidence of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) after immunosuppressive therapy (IST) for severe aplastic anemia (SAA). This European survey included 840 patients who received a first-line IST with (43%) or without (57%) G-CSF. The incidences of MDS/AML in patients who did or did not receive G-CSF were 10.9% and 5.8%, respectively. A significantly higher hazard (1.9) of MDS/AML was associated with use of G-CSF. Relapse of aplastic anemia was not associated with a worse outcome in patients who did not receive G-CSF as first therapy, whereas relapse was associated with a significantly worse outcome in those patients who received G-CSF. These results emphasize the necessity of the current European randomized trial comparing IST with or without G-CSF and to alert physicians that adding G-CSF to IST is currently not standard treatment for SAA.

scholarly journals Is the outcome of childhood acute myeloid leukemia with t(8;21) inferior in Saudi Arabia? A multicenter SAPHOS leukemia group study

2017 ◽  
Vol 8 (2) ◽  
pp. 41 ◽  
Author(s):  
Wasil Jastaniah ◽  
Abdulrahman Alsultan ◽  
Saad Al Daama ◽  
Walid Ballourah ◽  
Mohammad Bayoumy ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Saudi Arabia ◽  
Myeloid Leukemia ◽  
Childhood Acute Myeloid Leukemia ◽  
Leukemia Group ◽  
Acute Myeloid
Sign in / Sign up

Export Citation Format

Share Document